Enveric Biosciences Inc
Change company Symbol lookup
Select an option...
ENVB Enveric Biosciences Inc
BKE Buckle Inc
ROP Roper Technologies Inc
ESYJY Easyjet PLC
OGE OGE Energy Corp
ASB-E Associated Banc-Corp
LI Li Auto Inc
IKT Inhibikase Therapeutics Inc
GSIT GSI Technology Inc
AZRE Azure Power Global Ltd
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The Company through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The Company's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The Company is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.

Premarket

Last Trade
Delayed
$4.15
Change Since Close

Change Since Close

Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.

0.20 (5.06%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$3.95
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
2,168

10-day average volume:
20,035,812
2,168
Historical quotes & splits

Royal Caribbean Group Stock Underperforms Wednesday When Compared To Competitors

5:21 pm ET March 22, 2023 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Royal Caribbean Group (RCL) slipped 4.16% to $60.75 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 1.65% to 3,936.97 and Dow Jones Industrial Average falling 1.63% to 32,030.11. Royal Caribbean Group closed $26.93 short of its 52-week high ($87.68), which the company achieved on April 21st.

The stock underperformed when compared to some of its competitors Wednesday, as Walt Disney Co. (DIS) fell 1.70% to $94.90 and Carnival Corp. (CCL) fell 1.43% to $8.99. Trading volume (4.4 M) eclipsed its 50-day average volume of 4.0 M.

Data source: Dow Jones Market Data, FactSet. Data compiled March 22, 2023.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

March 22, 2023 17:21 ET (21:21 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.

3rd Party Research Disclosure